Drug intelligence / Profile preview

MK-2828

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-2828 is an investigational new molecular entity developed by Merck Sharp & Dohme for the treatment of Type 2 diabetes mellitus and cardiovascular disorders. It is classified as an antihyperglycaemic and therapy for vascular disorders. The precise mechanism of action for MK-2828 has not been defined or disclosed. MK-2828 is currently being studied in preclinical and early clinical (Phase 1) stages, including a randomized, placebo-controlled oral dosing study in participants with Type 2 diabetes, with endpoints measuring pharmacokinetics, safety, tolerability, and effects on high-sensitivity C-reactive protein (hsCRP)[1][3][7].

Targets

GPR52 (G protein-coupled receptor 52)

Beyond the preview

Go deeper on MK-2828.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-2828.

Explore the full profile